GlassScriptPhysician profile
Darin Kleinsmith
NPI 1275997629
$4,326.18
in general payments reported to CMS, 2019-2025
25 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $1,540 · 2023: $793 · 2024: $1,038 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.72 |
| Education | $193.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.45 | 2022-2025 | |
| Pfizer INC. | $715.21 | 2021-2025 | |
| Janssen Biotech, INC. | $624.32 | 2022-2025 | Tremfya |
| Incyte Corporation | $409.29 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $308.55 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $246.32 | 2022-2023 | Taltz, Olumiant |
| Biofrontera INC. | $160.04 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Almirall LLC | $156.42 | 2022 | |
| Ucb, INC. | $133.82 | 2023-2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $114.96 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $99.59 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $93.99 | 2022-2023 | |
| Amgen INC. | $90.24 | 2024 | Otezla |
| Revance Therapeutics, INC. | $80.53 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $73.22 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $63.53 | 2021-2024 | |
| Botanix Sb INC | $32.78 | 2025 | Sofdra |
| Dermira, INC. | $24.57 | 2021 | |
| Epi Health, LLC | $23.87 | 2021 | |
| Arcutis Biotherapeutics, INC. | $22.92 | 2024 | Zoryve |
| Vyne Pharmaceuticals INC. | $22.38 | 2021 | |
| Verrica Pharmaceuticals INC. | $18.54 | 2024 | Ycanth |
| Sebela Pharmaceuticals INC. | $18.41 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.15 | 2025 | Cabtreo |
| Bard Peripheral Vascular, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Kleinsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.